News & Events

Stay Current!

Integral to your Xentria journey is being informed about developments that matter to you.

Bookmark and visit this page to stay up to date.

  • All Posts
  • Happenings
  • Events
  • Products
  • Inside Xentria
2023 Year in Review
Inside Xentria

2023 Year in Review

December 19, 2023

Xentria's XTMAB-16 Receives Orphan Drug Designation from European Medicines Agency as First Patient Is Enrolled in Study
Inside Xentria

Xentria's XTMAB-16 Receives Orphan Drug Designation from European Medicines Agency as First Patient Is Enrolled in Study

November 15, 2023

Celebrating 40 Years of Orphan Drug Innovation
Happenings

Celebrating 40 Years of Orphan Drug Innovation

October 25, 2023

Viewpoint Project: Future of Healthcare - Innovative solutions
Happenings

Viewpoint Project: Future of Healthcare - Innovative solutions

July 27, 2023

Xentria’s Feature in Nature Biopharma Dealmakers
Inside Xentria

Xentria’s Feature in Nature Biopharma Dealmakers

July 11, 2023

Licensing Agreement to Commercialize XTMAB-16 in Sarcoidosis
Inside Xentria

Licensing Agreement to Commercialize XTMAB-16 in Sarcoidosis

June 27, 2023

ATS 2023: Join Us at our Clinical Trial Awareness Booth CT14 Hall D
Events

ATS 2023: Join Us at our Clinical Trial Awareness Booth CT14 Hall D

May 2023

Xentria Announces Peer Reviewed Publication of Biosim Model in Front. Pharmacol.
Happenings

Xentria Announces Peer Reviewed Publication of Biosim Model in Front. Pharmacol.

March 21, 2023

Xentria Announces $25 Million Financing Round to Advance Pipeline & Execute Growth Strategy
Products

Xentria Announces $25 Million Financing Round to Advance Pipeline & Execute Growth Strategy

October 18, 2022

Xentria Appoints Lead Scientific Advisor & Chief Operating Officer
Inside Xentria

Xentria Appoints Lead Scientific Advisor & Chief Operating Officer

August 4, 2022

FSR 2022 Global Virtual Patient Summit
Events

FSR 2022 Global Virtual Patient Summit

July 2022

Xentria Shares Initial Findings of Novel Biologic XTMAB-16’s Potential to Reduce Sarcoidosis Granuloma
Products

Xentria Shares Initial Findings of Novel Biologic XTMAB-16’s Potential to Reduce Sarcoidosis Granuloma

June 24, 2022

American Thoracic Society (ATS) International Conference 2022
Events

American Thoracic Society (ATS) International Conference 2022

May 13-18, 2022

Xentria to Present Initial Preclinical Findings of XTMAB-16 at ATS 2022 International Conference
Happenings

Xentria to Present Initial Preclinical Findings of XTMAB-16 at ATS 2022 International Conference

March 8, 2022

The Balancing Act Presents Behind the Mystery
Events

The Balancing Act Presents Behind the Mystery

December 2021

Xentria Highlights New Episode Of Lifetime® TV’s “Behind The Mystery” Segment Of “The Balancing Act®” On Sarcoidosis
Happenings

Xentria Highlights New Episode Of Lifetime® TV’s “Behind The Mystery” Segment Of “The Balancing Act®” On Sarcoidosis

December 6, 2021

WASOG/AASOG 2021: Multidisciplinary Meeting for Sarcoidosis and ILD
Events

WASOG/AASOG 2021: Multidisciplinary Meeting for Sarcoidosis and ILD

November 29 - December 2 2021

FSR 2021 Clinical Engagement Conference
Events

FSR 2021 Clinical Engagement Conference

October 2nd 2021

Xentria Initiates Clinical Trial for XTMAB-16 for the Treatment of Sarcoidosis
Products

Xentria Initiates Clinical Trial for XTMAB-16 for the Treatment of Sarcoidosis

June 22, 2021

FSR 2021 Virtual Patient Education Summit
Events

FSR 2021 Virtual Patient Education Summit

June 2021

NKF and Meitheal Announce Dr. Jiali Luo as General Manager of New Biopharmaceutical Business
Inside Xentria

NKF and Meitheal Announce Dr. Jiali Luo as General Manager of New Biopharmaceutical Business

May 20, 2021

Xentria Patient Focus Group: Living with Sarcoidosis
Events

Xentria Patient Focus Group: Living with Sarcoidosis

April 2021

Xentria Submits IND Application for XTMAB-16 in the Treatment of Sarcoidosis
Inside Xentria

Xentria Submits IND Application for XTMAB-16 in the Treatment of Sarcoidosis

March 3, 2021

Xentria Announces FDA Orphan Drug Designation for XTMAB-16 in Sarcoidosis
Products

Xentria Announces FDA Orphan Drug Designation for XTMAB-16 in Sarcoidosis

December 15, 2020

No articles found. Please try a different category.

Contact Us